Cargando…

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer

SIMPLE SUMMARY: Despite the implementation of efficient screening and vaccination programs, uterine cervical cancer remains a leading cause of cancer-related mortality in women worldwide. New therapeutic approaches have so far failed to improve treatment response and prognosis significantly, especia...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Maximilian, Chatzikonstantinou, Georgios, Fokas, Emmanouil, Wichmann, Jörn, Christiansen, Hans, Strebhardt, Klaus, Rödel, Claus, Tselis, Nikolaos, Rödel, Franz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616420/
https://www.ncbi.nlm.nih.gov/pubmed/34830902
http://dx.doi.org/10.3390/cancers13225748
_version_ 1784604343998087168
author Fleischmann, Maximilian
Chatzikonstantinou, Georgios
Fokas, Emmanouil
Wichmann, Jörn
Christiansen, Hans
Strebhardt, Klaus
Rödel, Claus
Tselis, Nikolaos
Rödel, Franz
author_facet Fleischmann, Maximilian
Chatzikonstantinou, Georgios
Fokas, Emmanouil
Wichmann, Jörn
Christiansen, Hans
Strebhardt, Klaus
Rödel, Claus
Tselis, Nikolaos
Rödel, Franz
author_sort Fleischmann, Maximilian
collection PubMed
description SIMPLE SUMMARY: Despite the implementation of efficient screening and vaccination programs, uterine cervical cancer remains a leading cause of cancer-related mortality in women worldwide. New therapeutic approaches have so far failed to improve treatment response and prognosis significantly, especially in patients with recurrent disease or metastases. Further, robust molecular markers to predict therapy response and survival are scarce and their routine use is limited in clinical practice. Accordingly, there is an urgent need to identify and establish molecular markers to predict therapy response and clinical outcome to improve treatment and survival in cervical cancer. ABSTRACT: Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000 deaths. While less-invasive, fertility-preserving surgical procedures can be offered to women in early stages, treatment for locally advanced disease may include radical hysterectomy, primary chemoradiotherapy (CRT) or a combination of these modalities. Concurrent platinum-based chemoradiotherapy regimens remain the first-line treatments for locally advanced cervical cancer. Despite achievements such as the introduction of angiogenesis inhibitors, and more recently immunotherapies, the overall survival of women with persistent, recurrent or metastatic disease has not been extended significantly in the last decades. Furthermore, a broad spectrum of molecular markers to predict therapy response and survival and to identify patients with high- and low-risk constellations is missing. Implementation of these markers, however, may help to further improve treatment and to develop new targeted therapies. This review aims to provide comprehensive insights into the complex mechanisms of cervical cancer pathogenesis within the context of molecular markers for predicting treatment response and prognosis.
format Online
Article
Text
id pubmed-8616420
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86164202021-11-26 Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer Fleischmann, Maximilian Chatzikonstantinou, Georgios Fokas, Emmanouil Wichmann, Jörn Christiansen, Hans Strebhardt, Klaus Rödel, Claus Tselis, Nikolaos Rödel, Franz Cancers (Basel) Review SIMPLE SUMMARY: Despite the implementation of efficient screening and vaccination programs, uterine cervical cancer remains a leading cause of cancer-related mortality in women worldwide. New therapeutic approaches have so far failed to improve treatment response and prognosis significantly, especially in patients with recurrent disease or metastases. Further, robust molecular markers to predict therapy response and survival are scarce and their routine use is limited in clinical practice. Accordingly, there is an urgent need to identify and establish molecular markers to predict therapy response and clinical outcome to improve treatment and survival in cervical cancer. ABSTRACT: Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000 deaths. While less-invasive, fertility-preserving surgical procedures can be offered to women in early stages, treatment for locally advanced disease may include radical hysterectomy, primary chemoradiotherapy (CRT) or a combination of these modalities. Concurrent platinum-based chemoradiotherapy regimens remain the first-line treatments for locally advanced cervical cancer. Despite achievements such as the introduction of angiogenesis inhibitors, and more recently immunotherapies, the overall survival of women with persistent, recurrent or metastatic disease has not been extended significantly in the last decades. Furthermore, a broad spectrum of molecular markers to predict therapy response and survival and to identify patients with high- and low-risk constellations is missing. Implementation of these markers, however, may help to further improve treatment and to develop new targeted therapies. This review aims to provide comprehensive insights into the complex mechanisms of cervical cancer pathogenesis within the context of molecular markers for predicting treatment response and prognosis. MDPI 2021-11-17 /pmc/articles/PMC8616420/ /pubmed/34830902 http://dx.doi.org/10.3390/cancers13225748 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fleischmann, Maximilian
Chatzikonstantinou, Georgios
Fokas, Emmanouil
Wichmann, Jörn
Christiansen, Hans
Strebhardt, Klaus
Rödel, Claus
Tselis, Nikolaos
Rödel, Franz
Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_full Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_fullStr Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_full_unstemmed Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_short Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
title_sort molecular markers to predict prognosis and treatment response in uterine cervical cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616420/
https://www.ncbi.nlm.nih.gov/pubmed/34830902
http://dx.doi.org/10.3390/cancers13225748
work_keys_str_mv AT fleischmannmaximilian molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer
AT chatzikonstantinougeorgios molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer
AT fokasemmanouil molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer
AT wichmannjorn molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer
AT christiansenhans molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer
AT strebhardtklaus molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer
AT rodelclaus molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer
AT tselisnikolaos molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer
AT rodelfranz molecularmarkerstopredictprognosisandtreatmentresponseinuterinecervicalcancer